Methodology

All entries for: Antiviral

August 2, 2024

Vir Biotechnology

Discontinued Research, Layoffs

San Francisco, CA
201-500 employees
201-500 employees

“As part of its second-quarter business results, Vir revealed that it will no longer be continuing its work in COVID-19 and influenza, while pulling the plug on its T-cell-based viral vector platform. Instead, the biotech will restrict its virology business to its hepatitis B and D programs, allowing it to focus only on the “highest near-term value opportunities.”

“Under Vir’s strategic overhaul, the biotech will lay off 25% of its workforce, eliminating approximately 140 roles across its operations.”

“Vir now expects to close out the year with around 435 employees, which is some 200 employees fewer from its peak headcount in mid-2023.”

3 Discontinued Research Programs: COVID-19, influenza, and T-cell-based viral vector platform research programs.

Disease Area: Antiviral, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
November 8, 2023

Atea Pharmaceuticals

Negative Outlook

Boston, MA
51-200 employees
51-200 employees

“We expect that additional US federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the US federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.”

Disease Area: Antiviral
Drug Type: Small Molecule
Source
November 7, 2023

Gilead

Negative Outlook

Foster City, CA
10,001-50,000 employees
10001-50000 employees

“While the full impact of the Act on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the Act will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.”

Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
Source
October 27, 2023

Vir Biotechnology

Negative Outlook

San Francisco, CA
201-500 employees
201-500 employees

“Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.”

Disease Area: Antiviral, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
August 5, 2023

Atea Pharmaceuticals

Negative Outlook

Boston, MA
51-200 employees
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
Source
August 4, 2023

Gilead

Negative Outlook

Foster City, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
Source
May 5, 2023

Atea Pharmaceuticals

Negative Outlook

Boston, MA
51-200 employees
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
Source
May 3, 2023

Gilead

Negative Outlook

Foster City, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
Source
November 7, 2022

Atea Pharmaceuticals

Negative Outlook

Boston, MA
51-200 employees
51-200 employees

Likely Signigifant: “Most significantly, on August 16, 2022, President Biden signed the IRA into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010… For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.”

Disease Area: Antiviral
Drug Type: Small Molecule
Source
November 2, 2022

Gilead

Negative Outlook

Foster City, CA
10,001-50,000 employees
10001-50000 employees

• Potential for Limiting Prices, More Rebates: “We are continuing to evaluate the impact of the Act on our business, but it is possible that the Act could have the effect of limiting the prices we can charge and increasing the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results” • Additional Leg/Rulemaking: “We cannot be sure whether additional legislation or rulemaking related to the Act will be issued or enacted, or what impact, if any, such changes will have on the profitability of our business in the future” • Uncertainty: “These initiatives and such other legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain”

Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
Source
Facebook Linkedin
Main Menu
Scroll to Top